CLINICAL TRIALS AND OBSERVATIONS Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
نویسندگان
چکیده
1Johns Hopkins School of Medicine, Baltimore, MD; 2National Heart, Lung, and Blood Institute, Bethesda, MD; 3University of Florence, Florence, Italy; 4Federico II University of Naples, Naples, Italy; 5Institute of Transfusion Medicine, University Hospital Institute of Clinical Transfusion Medicine and Immunogenetics, Ulm; DRK-Blood Donor Service Baden-Württemberg-Hessen, Germany; 6Saarland University Medical School, Homburg-Saarland, Germany; 7Hospital Clinic of Barcelona, Institut d’Investigacions Biomedique Augist Pi i Sunyer (IDIBAPS), Barcelona, Spain; 8Royal North Shore Hospital, St Leonards, Australia; 9Duke University Medical Center, Durham, NC; 10Cleveland Clinic Florida, Weston, FL; 11Taussig Cancer Center, Cleveland Clinic, OH; 12Washington University in St Louis, MO; 13Alexion Pharmaceuticals, Cheshire, CT; and 14St James’s Institute of Oncology, Leeds, United Kingdom
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
This multicenter phase 2 study evaluated the use of tipifarnib (R115777) in patients with poor-risk myelodysplastic syndrome (MDS; French-American-British classification). Patients (n 82) received tipifarnib 300 mg orally twice daily for the first 21 days of each 28-day cycle. Twenty-six patients (32%) responded to tipifarnib: 12 (15%) complete responses (CRs) and 14 (17%) hematologic improveme...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
The CANAL Study (Concerted Action on Neutralizing Antibodies in severe hemophilia A) was designed to describe the relationship between treatment characteristics and inhibitor development in previously untreated patients with severe hemophilia A. This multicenter retrospective cohort study investigated 366 consecutive patients born between 1990 and 2000. The outcome was clinically relevant inhib...
متن کاملI-12: Objective Embryo Assessment Utility of Time-Lapse
Background Traditionally, embryo incubation and assessment daily has been under a light microscope, these observations are inevitably restricted to specific times and considering that the development of the embryo is a dynamic process, several critical stages in between observations may go unnoticed. For this reason, the new technologies, time lapse monitoring, have focused on the research for ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
Rituximab is a chimeric monoclonal antibody that targets B-cell–specific antigen CD20 and an effective treatment for B-cell non-Hodgkin lymphoma. Although it is readily used in clinical practice, the exact mechanism of its antitumor effect is unclear. One potential mechanism involves complement-mediated cytotoxicity. It has been shown that rituximab induces complement-mediated cytotoxicity in f...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors for the achievement of complete cytogenetic re...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2008